C4 Therapeutics (CCCC) Insider Laura Bessen Buys 62,000 Shares

Multiple Insiders Acquire C4 Therapeutics Shares

C4 Therapeutics, Inc. (NasdaqGS: CCCC) saw a wave of internal activity on June 24, 2026, when insider Laura Bessen acquired 62,000 shares of the clinical-stage biotechnology company. This transaction follows a pattern of parallel purchases made on the same date by several other key figures at the firm.

A Group Purchase by Leadership

The transaction by Laura Bessen was mirrored by five other individuals within the organization on June 24, 2026. Ronald Ronald Harold Wilfred Cooper, Utpal Koppikar, Donna Roy Grogan, Owen Hughes, and Stephen Fawell each also acquired 62,000 shares of C4 Therapeutics, Inc. on that date. These coordinated transactions bring a notable block of shared acquisitions into focus for market watchers tracking internal sentiment at the Watertown-based biotech.

Stock Performance and Valuation

Shares of C4 Therapeutics, Inc. change hands at $4.40. The company carries a market capitalization of approximately $406.0 million. The equity moves within a 52-week band that stretches from a low of $1.69 up to $5.17, positioning the current trading price closer to the higher end of that range. Because the firm is not currently profitable, it has no meaningful P/E ratio, though its forward P/E sits at -3.31.

Analysts Set New Price Targets

Wall Street firms maintain active coverage on the biotechnology company. On October 9, 2026, JP Morgan initiated coverage on the stock with an overweight rating and a $10.00 price target. Across the broader analyst community, six analysts offer opinions with a consensus target mean price of $13.33.

Focus on Targeted Protein Degradation

C4 Therapeutics, Inc. develops therapeutic candidates designed to degrade disease-causing proteins. Its pipeline includes candidates targeting multiple myeloma and non-small cell lung cancer, alongside research into inflammation and neurodegeneration. Internal transactions of this nature offer a window into how people close to the enterprise manage their personal stakes while clinical programs advance.

Looking Ahead at Upcoming Milestones

Investors tracking C4 Therapeutics, Inc. should mark their calendars for the next financial results release, which is scheduled for November 5, 2026. That report will provide further insight into the company's financial standing and clinical progress. Internal purchases filed via regulatory forms reflect past positioning and do not necessarily guarantee future shifts in market direction.